Differing early blood pressure and renin-angiotensin system responses to the first dose of angiotensin-converting enzyme inhibitors in congestive heart failure

Journal of Cardiovascular Pharmacology

Volumn 27, Issue 5, 1996, Pages 657-666

  Squire, I B ^a,b   MacFadyen, R J ^a   Reid, J L ^a   Devlin, A ^a   Lees, K R ^a  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

^b UNIVERSITY OF LEICESTER   (United Kingdom)

Author keywords

Angiotensin; Converting enzyme inhibitors; Haemodynamic response; Heart failure; Neurohormonal response

Indexed keywords

ANGIOTENSIN; ANGIOTENSIN I; DIPEPTIDYL CARBOXYPEPTIDASE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; NEUROHORMONE; PERINDOPRIL; PERINDOPRILAT; PLACEBO; RENIN;

ADULT; AGED; ARTICLE; BLOOD PRESSURE MEASUREMENT; CLINICAL ARTICLE; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; ENZYME INHIBITION; FEMALE; HEART RATE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALE; MEAN ARTERIAL PRESSURE; ORAL DRUG ADMINISTRATION; PLASMA RENIN ACTIVITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM;

AGED; AGED, 80 AND OVER; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; BLOOD PRESSURE; DOUBLE-BLIND METHOD; ENALAPRIL; FEMALE; HEART FAILURE, CONGESTIVE; HEART RATE; HUMANS; INDOLES; MALE; MIDDLE AGED; PERINDOPRIL; RENIN; RENIN-ANGIOTENSIN SYSTEM;

EID: 0029935127     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/00005344-199605000-00007     Document Type: Article

References (44)

1. AIRE Study Group. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. Lancet 1993;342:821-8.
2. The CONSENSUS Trial Study Group. Effect of enalapril on mortality in severe congestive cardiac failure: results of the Cooperative North Scandinavian Trial Group. N Engl J Med 1987;316: 1429-35.
3. Pfeffer MA, Braunwald E, Moye LA, et al., on behalf of the SAVE investigators. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 1992;327:669-77.
4. The SOLVD investigators. Effects of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991;325:293-302.
5. The SOLVD investigators. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med 1992;327: 685-91.
6. Cohn JN, Johnson G, Ziesche S, et al. A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of congestive heart failure. N Engl J Med 1991;325:303-10.
7. Cleland JGF, Dargie HJ, McAlpine H, Ball SG, Robertson JIS, Ford I. Severe hypotension after first dose of enalapril in heart failure. Br Med J 1985;291:1309-12.
8. Sharpe DN, Coxon RJ, Douglas JE, Long B. Low dose captopril in chronic heart failure: haemodynamic effects and long term treatment. Lancet 1980;2:1154-7.
9. Conway M, Mohideen R, Adamopolous S, Flather M, Collins R, Sleight P. A dose-finding study for the initiation of captopril within 24 h of acute myocardial infarction. Q J Med 1989;73:973-4.
10. Packer M, Kessler, P. Gottlieb SS. Adverse effects of converting enzyme inhibition in patients with severe congestive heart failure: pathophysiology and management. Postgrad Med J 1986;62(suppl 1):179-82.
11. Mujais SK, Fouad FM, Textor SC, et al. Transient renal dysfunction during initial inhibition of converting enzyme in congestive heart failure. Br Heart J 1984;52:63-71.
12. McMurray J, Lang CC, Maclean DD, McDevitt DG, Struthers AD. A survey of current use of angiotensin converting enzyme inhibitors by Scottish physicians in the treatment of chronic cardiac failure. Scot Med J 1989;34:425-7.
13. Bayliss J, Norell M, Canepa-Anson R, Sutton G, Poole-Wilson P. Untreated heart failure: clinical and neuro-endocrine effects of introducing diuretics. Br Heart J 1987;57:17-22.
14. Anand IS, Ferrari R, Kalra GS, Wahi PL, Poole-Wilson PA, Harris PC. Edema of cardiac origin: studies of body water and sodium, renal functions, hemodynamic indexes and plasma hormones in untreated congestive cardiac failure. Circulation 1989;80:299-305.
15. Shepherd JT, Mancia G. Reflex control of the human cardiovascular system. Rev Physiol Biochem Pharmacol 1986;105:1-99.
16. Packer M. Identification of risk factors predisposing to the development of functional renal insufficiency during treatment with converting enzyme inhibitors in chronic heart failure. Cardiology 1989;76(suppl 2):50-5.
17. Motwani JG, Fenwick MK, Morton JJ, Struthers AD. Determinants of the initial effects of captopril on blood pressure, glomerular filtration rate, and natriuresis in mild to moderate chronic congestive heart failure secondary to coronary artery disease. Am J Cardiol 1994;73:1191-6.
18. Kjeckshus J, Swedberg K. Importance of first-dose hypotension with enalaprilat in acute myocardial infarction. J Am Coll Cardiol 1992;19:206A.
19. MacFadyen RJ, Lees KR, Reid JL. Differences in first dose response to angiotensin converting enzyme inhibition in congestive heart failure: a placebo controlled study. Br Heart J 1991;66:206-11.
20. MacFadyen RJ, Lees KR, Reid JL. Double blind controlled study of low dose intravenous perindoprilat or enalaprilat infusion in elderly patients with heart failure. Br Heart J 1993;69:293-8.
21. Harrigan JR, Hughes DM, Meredith PA, Reid JL. Characterisation of the effects of prodrug concentration on the in vitro potency of metabolites of five ACE inhibitors [Abstract]. Eur J Clin Pharmacol 1989;36(suppl.):A186.
22. Ryan JW, Chung AYK, Berryer P, Murray MA, Ryan JPA. Slow tight binding inhibitors of angiotensin converting enzyme. Ad Exp Med Biol 1986;198:419-25.
23. Nussberger J, Juillerat L, Perret F, et al. Need for plasma angiotensin measurements to investigate converting enzyme inhibition in humans. Am Heart J 1989;117:717-22.
24. Derkx FHL, Tan-Tjiong HL, Man Int Veld AJ, Schalekamp MADH. Activation of inactive plasma renin and tissue kallikreins. Clin Sci 1979;57:351-7.
25. Chiknas S. Liquid chromatography assisted assay for ACE in serum. Clin Chem 1979;25:1259-62.
26. Nussberger J, Brunner DB, Waeber B, Brunner HR. True versus immunoreactive angiotensin II in human plasma. Hypertension 1985;7(suppl 1):I1-7.
27. Devlin AM. Development of an analytical method for the specific assay of angiotensin II in human plasma by the combination of h.p.l.c. with r.i.a. Br J Clin Pharmacol 1992;34:457P.
28. Waeber B, Brunner HR, Brunner DB, Curtet AL, Turning B, Gavras H. Discrepancy between antihypertensive effect and angiotensin converting enzyme inhibition by captopril. Hypertension 1980;2:236-42.
29. Unger T, Ganten D, Lang RE. Tissue converting enzyme and cardiovascular actions of converting enzyme inhibitors. J Cardiovasc Pharmacol 1986;8(suppl 10):S75-81.
30. Nussberger J, Brunner DB, Waeber B, Brunner HR. Specific measurement of angiotensin metabolites and in vitro generated angiotensin II in plasma. Hypertension 1986;8:476-82.
31. Nussberger J, Brunner DB, Waeber B, Brunner HR. In vitro renin inhibition to prevent generation of angiotensins during determination of angiotensin I and II. Life Sci 1988;42:1683-8.
32. Devissaguet JP, Ammoury N, Devissaguet N, Perret L. Pharmacokinetics of perindopril and its metabolites in healthy volunteers. Fund Clin Pharmacol 1990;4:175-89.
33. Lees KR, Green St, Reid JL. Influence of age on the pharmacokinetics and pharmacodynamics of perindopril. Clin Pharmacol Ther 1988;44:418-25.
34. Weisser K, Schloos J, Lehmann K, et al. Pharmacokinetics and converting enzyme inhibition after morning and evening administration of oral enalapril to healthy subjects. Eur J Clin Pharmacol 1991;40:95-9.
35. Johnston CI. Angiotensin converting enzyme inhibitors. In: Doyle AE, ed. Handbook of hypertension. Vol. 11; antihypertensive drugs. Amsterdam: Elsevier, 301-26.
36. Thind GS. Angiotensin converting enzyme inhibitors: comparative structure, pharmacokinetics, and pharmacodynamics. Cardiovasc Drugs Ther 1990;4:199-206.
37. Fabris B, Jackson B, Kohzuki M, Pehrich R, Johnston CI. Increased cardiac angiotensin enzyme in rats with chronic heart failure. Clin Exp Pharmacol Physiol 1990;17:309-14.
38. Hirsch AT, Talsness CE, Smith AD, Schunkert H, Ingelfinger JR, Dzau VJ. Differential effects of captopril and enalapril on tissue renin-angiotensin systems in experimental heart failure. Circulation 1992;86:1566-74.
39. Lees KR, Reid JL. Haemodynamic and humoral effects of oral perindopril, an angiotensin converting enzyme inhibitor, in man. Br J Clin Pharmacol 1987;23:159-64.
40. Asmar RG, Journo HJ, Lacolley PJ, et al. Treatment for one year with perindopril: effect on cardiac mass and arterial compliance in essential hypertension. J Hypertens 1988;6(suppl 3):S33-9.
41. Bounhoure JP, Bottineau G, Lechat P, Garnham J, Lapeyre G. Value of perindopril in the treatment of chronic congestive heart failure. Clin Exp Hypertens [A] 1989;11(suppl 2):575-86.
42. Flammang D, Waynberger M, Chassang A, Lafore B, Bottineau G. Acute and long-term haemodynamic efficacy of oral perindopril in severe heart failure [Abstract]. Eur Heart J 1990;11(suppl):56.
43. Nussberger J, Fleck E, Bahrman H, Delius W, Schultheiss HP, Brunner HR. Dose-related effects of ACE inhibition in man: quinapril in patients with moderate congestive heart failure. Eur Heat J 1994;15(suppl D):113-22.
44. Squire IB, Macfadyen RJ, Lees KR, Hillis WS, Reid JL. Haemodynamic response and pharmacokinetics after the first dose of quinapril in patients with congestive heart failure. Br J Clin Pharmacol 1994;38:117-23.